Stomach Cancer Treatment Market By Treatment Type (Chemotherapy, Immunotherapy, Targeted Therapy, Antibody–Drug Conjugates, Cellular Therapy, Surgery and Endoscopic Treatment, Radiation Therapy, Supportive Care); By Application (Early-Stage Stomach Cancer, Resectable Locally Advanced Stomach Cancer, Unresectable Locally Advanced Stomach Cancer, Metastatic Stomach Cancer, Recurrent Stomach Cancer); By End User (Hospitals, Specialty Cancer Centers, Ambulatory Infusion Centers, Surgical Centers, Cellular Therapy Centers); By Biomarker (HER2-Positive, PD-L1-Positive, CLDN18.2-Positive, MSI-High/dMMR, EBV-Positive, Biomarker-Negative or Unselected); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Stomach Cancer Treatment Market: Biomarker Sequencing and Perioperative Immunotherapy Expand Treatment Value

The Global Stomach Cancer Treatment Market was valued at USD 7.29 billion in 2025 and is projected to reach USD 11.86 billion by 2032, expanding at a 7.2% CAGR during the forecast period, according to Strategic Market Research.

 

The Stomach Cancer Treatment Market is moving beyond a treatment model centred on gastrectomy and cytotoxic chemotherapy. Approvals between 2024 and 2026 have divided the patient population by disease stage, HER2 status, PD-L1 expression, CLDN18.2 expression, microsatellite instability, and previous treatment exposure. Biomarker results now determine whether patients receive checkpoint inhibitors, targeted antibodies, antibody–drug conjugates, or cellular therapies.

 

Durvalumab has introduced branded immunotherapy into curative-intent treatment. Zolbetuximab has established CLDN18.2-positive disease as a first-line treatment category. Pembrolizumab-based regimens have increased treatment intensity in both HER2-negative and HER2-positive advanced disease. China’s June 2026 approval of satri-cel created the first commercial CAR-T pathway for a solid tumor.

 

Revenue growth will increasingly depend on the number of patients tested, the proportion meeting biomarker thresholds, treatment duration, combination use, reimbursement, and the ability of new products to improve survival against established regimens. Incidence alone no longer provides a reliable measure of the addressable treatment population.

 

Late Diagnosis Keeps Systemic Treatment Demand High

GLOBOCAN estimated 980,286 new stomach cancer cases and 641,554 deaths worldwide in 2024, placing the disease fifth for both incidence and cancer mortality. Asia accounted for 694,188 cases, or 70.8% of global incidence, and 446,955 deaths, representing 69.7% of mortality.

Approximately 1.68 million people were living within five years of a stomach cancer diagnosis, including 1.25 million in Asia. These patients generate continued demand for postoperative surveillance, nutritional care, adjuvant treatment, recurrence management, molecular testing, and later-line systemic therapy.

The United States is expected to record 31,510 new cases and 10,740 deaths in 2026. Only 32% of U.S. cases are localized at diagnosis, while 23% are regional and 35% are metastatic. Five-year relative survival falls from 78.1% for localized disease to 39.0% for regional disease and 8.1% for metastatic disease.

Around 58% of U.S. patients therefore enter treatment with regional or metastatic cancer, before including patients who relapse after surgery. This stage distribution sustains demand for perioperative chemotherapy, immunotherapy, first-line combinations, and subsequent targeted treatments.

The median U.S. diagnosis age is 68 years, with more than 60% of cases occurring in patients aged 65 or older. Older patients frequently have reduced tolerance for intensive chemotherapy, major gastrectomy, and cellular therapy. Regimens that preserve efficacy while reducing hospitalization, severe toxicity, nutritional deterioration, and treatment discontinuation are likely to gain stronger clinical acceptance.

Regional screening practices also change treatment spending. Japan and South Korea detect more superficial tumors that can be removed endoscopically or treated through earlier surgery. The United States and several European markets diagnose a larger proportion after local or distant progression, increasing systemic drug use per patient.

 

Durvalumab Extends Immunotherapy Across the Surgical Pathway

Perioperative FLOT became a major Western treatment standard after the FLOT4 trial increased median overall survival from 35 months with ECF or ECX to 50 months. The regimen improved outcomes but relied on established chemotherapy agents with limited branded pricing.

Durvalumab has added premium immunotherapy before and after surgery. The FDA approved durvalumab with perioperative FLOT in November 2025 for resectable stage II to IVA gastric or gastroesophageal-junction adenocarcinoma.

MATTERHORN enrolled 948 patients. Median event-free survival was not reached with durvalumab and FLOT, compared with 32.8 months for FLOT alone, producing a hazard ratio of 0.71. Pathological complete response increased from 7.2% to 19.2%, while the overall-survival hazard ratio reached 0.78.

Patients receive durvalumab with chemotherapy before surgery, resume treatment after surgery, and may continue durvalumab alone for up to ten additional cycles. AstraZeneca can therefore generate treatment revenue across several stages of the curative pathway rather than relying on metastatic use after recurrence.

NICE recommended perioperative durvalumab with FLOT in May 2026 and estimated that more than 1,500 patients in England could become eligible each year. Two-year event-free survival reached 67.4% with durvalumab and FLOT, compared with 58.5% for FLOT alone.

Public reimbursement in England indicates that recurrence reduction and survival evidence can support adoption even when treatment extends over several months. Competing checkpoint inhibitors will need to improve event-free or overall survival without reducing surgical completion or increasing postoperative complications.

Pathological response alone is unlikely to support broad reimbursement. Clinicians and payers will focus on recurrence patterns, overall survival, treatment discontinuation, immune-related adverse events, and the cost of prolonged postoperative therapy.

 

First-Line Advanced Treatment Has Split Into Biomarker-Defined Groups

Chemotherapy remains the backbone of advanced stomach cancer treatment, but biomarker results now determine which branded agent is added. HER2, PD-L1, CLDN18.2, MSI, and mismatch-repair status directly affect first-line selection.

KEYNOTE-859 enrolled 1,579 patients with HER2-negative advanced gastric or gastroesophageal-junction adenocarcinoma. Pembrolizumab plus chemotherapy increased median overall survival from 11.5 to 12.9 months, progression-free survival from 5.6 to 6.9 months, and response rate from 42% to 51%.

Pembrolizumab can continue until disease progression, unacceptable toxicity, or the permitted treatment-duration limit, creating recurring infusion revenue across a large HER2-negative population. The modest absolute survival improvement in the overall study population may encourage payers to concentrate reimbursement in patients with higher PD-L1 expression.

HER2-positive and PD-L1-positive disease supports an even more intensive treatment combination. KEYNOTE-811 increased median overall survival from 15.7 months with trastuzumab and chemotherapy to 20.1 months with pembrolizumab, trastuzumab, and chemotherapy. Progression-free survival increased from 7.3 to 10.9 months, while response rate rose from 58% to 73%.

Two branded biologic agents now participate in the same first-line course. New HER2 therapies must compete against trastuzumab combined with checkpoint inhibition rather than against trastuzumab and chemotherapy alone. Higher survival, broader biomarker eligibility, lower toxicity, or easier administration will be required to displace the current regimen.

 

CLDN18.2 Has Become a Treatment Platform

The FDA approved zolbetuximab in October 2024 for first-line treatment of CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric and gastroesophageal-junction adenocarcinoma. Approval of Roche’s companion assay at the same time made pathology testing a formal part of treatment access.

SPOTLIGHT reported median overall survival of 18.2 months with zolbetuximab and mFOLFOX6, compared with 15.5 months for chemotherapy alone. Median progression-free survival increased from 8.7 to 10.6 months.

GLOW reported median overall survival of 14.4 months with zolbetuximab and CAPOX, compared with 12.2 months for chemotherapy. Progression-free survival increased from 6.8 to 8.2 months.

U.S. eligibility requires moderate-to-strong CLDN18 staining in at least 75% of viable tumor cells. The strict assay threshold narrows the patient pool before performance status, disease stage, and chemotherapy eligibility are considered.

Gastrointestinal toxicity may also reduce treatment persistence. Nausea, vomiting, reduced appetite, and infusion-related management can delay treatment or lead to discontinuation. Astellas’ uptake will depend on pathology turnaround, antiemetic protocols, infusion-centre experience, and consistent assay use.

Scotland issued a national reimbursement recommendation for zolbetuximab in January 2026, becoming the first UK nation to adopt a CLDN18.2-directed gastric cancer treatment. The assessment estimated that approximately 38% of relevant advanced HER2-negative tumors could meet the required expression threshold.

National reimbursement changes CLDN18.2 testing from optional profiling into a treatment requirement. Laboratories, pathology providers, companion-diagnostic manufacturers, and oncology centres all gain from wider testing coverage.

CLDN18.2 now supports more than monoclonal antibody treatment. China approved CARsgen’s satri-cel in June 2026 for previously treated CLDN18.2-positive advanced gastric or gastroesophageal-junction cancer. Satri-cel became the first approved CAR-T therapy for a solid tumor.

The randomized CT041-ST-01 study reported median progression-free survival of 3.25 months with satri-cel, compared with 1.77 months for physician-selected treatment. Median overall survival reached 7.92 months versus 5.49 months.

Grade 3 or higher treatment-emergent adverse events occurred in 99% of treated patients. Uptake will therefore remain concentrated among fit patients treated at centres capable of managing lymphodepletion, cell manufacturing, inpatient monitoring, and immune-related complications.

CARsgen expected approximately 200 orders during the second half of 2026. The initial launch is likely to remain small, but approval validates CLDN18.2 as a cellular-therapy target and gives China an early position in solid-tumor CAR-T commercialization.

Expansion into earlier treatment lines or additional countries would increase the addressable population. Manufacturing time, centre capacity, toxicity, and treatment cost currently impose tighter limits than biomarker prevalence.

 

Zanidatamab Could Disrupt the HER2 Treatment Sequence

Trastuzumab remains the first-line HER2 backbone, while trastuzumab deruxtecan has established a later-line antibody–drug conjugate segment. DESTINY-Gastric01 increased median overall survival from 8.4 months with physician-selected chemotherapy to 12.5 months with trastuzumab deruxtecan.

Continued HER2 targeting after trastuzumab failure allows manufacturers to participate across more than one treatment line. Repeat HER2 testing may become more important because expression can vary across tumor sites and decline after previous HER2-directed treatment.

Jazz Pharmaceuticals’ zanidatamab could challenge the first-line standard. HERIZON-GEA-01 enrolled 914 patients and compared zanidatamab-based regimens with trastuzumab and chemotherapy.

Zanidatamab with tislelizumab and chemotherapy produced median progression-free survival of 12.4 months, compared with 8.1 months for trastuzumab and chemotherapy. Median overall survival reached 26.4 months versus 19.2 months, although the first interim analysis did not cross the prespecified statistical threshold for overall survival.

The FDA granted Priority Review with an August 25, 2026 action date. Approval would give Jazz Pharmaceuticals and BeiGene direct access to the first-line HER2-positive market and could weaken trastuzumab’s position as the default targeted backbone.

Tolerability may influence prescribing. Grade 3 or higher treatment-related adverse events occurred in 71.8% of patients receiving zanidatamab, tislelizumab, and chemotherapy. At least one treatment component was discontinued in 42.5% of patients.

The survival signal supports strong clinical interest, but treatment discontinuation and cumulative toxicity may limit routine use in older or medically fragile patients. Final overall-survival analysis and regulatory labelling will determine how broadly the regimen competes with pembrolizumab, trastuzumab, and chemotherapy.

Henlius is pursuing a dual-HER2 strategy with HLX22 added to trastuzumab and chemotherapy. The FDA granted orphan-drug designation in March 2025, and global Phase III development is underway. HLX22 could add another branded biologic to the first-line regimen without requiring clinicians to abandon trastuzumab.

 

Pipeline Setbacks Are Removing Weak Biomarker Strategies

FGFR2b-directed bemarituzumab illustrates the risk of relying on early survival signals. FORTITUDE-101 initially reported median overall survival of 17.9 months with bemarituzumab and chemotherapy, compared with 12.5 months for chemotherapy alone.

Longer follow-up reduced the difference to 14.5 versus 13.2 months, while the hazard ratio weakened from 0.61 to 0.82. Objective response remained almost unchanged at 45.9% versus 44.8%.

Amgen later halted FORTITUDE-102 after an efficacy review failed to meet its development criteria. FGFR2b remains biologically relevant, but it has not developed into a validated treatment or testing segment.

Tivumecirnon may offer a narrower route in EBV-positive disease, but EBV-positive tumors represent a small molecular subgroup. BOLD-100 has reported lower oxaliplatin-related neuropathy than historical benchmarks, although the comparison was not randomized.

Neither program currently supports broad revenue assumptions. Randomized efficacy, reproducible biomarker selection, treatment-line clarity, and acceptable toxicity will determine whether these assets progress beyond specialist clinical interest.

 

Testing Capacity Determines How Many Patients Reach Targeted Therapy

The SAPHIR registry evaluated 473 patients with metastatic gastric or gastroesophageal-junction adenocarcinoma. Central testing identified HER2 positivity in 11.8%, CLDN18.2 positivity in 26.7%, MSI-high or mismatch-repair-deficient disease in 2.5%, and EBV positivity in 0.6%.

Routine testing reached 78.6% for HER2 but only 31.3% for PD-L1 and 15.6% for MSI. Local and central results differed by 12.4% for HER2 and 22.4% for PD-L1.

Eligible patients are lost when tissue is inadequate, testing is not ordered, assays are unavailable, or pathology results differ across laboratories. Drug manufacturers must therefore support reflex-testing protocols, laboratory training, tissue-preservation standards, reimbursement, and repeat-biopsy pathways.

HER2, PD-L1, CLDN18.2, and MSI populations can overlap, and expression may change after treatment. Sequential targeted therapy will increase demand for repeat pathology and may support greater use of liquid biopsy where tissue collection is difficult.

 

Asia Leads Patient Volume While the U.S. Leads High-Value Adoption

Asia will remain the largest regional treatment market because it accounts for more than 70% of global incidence and nearly 75% of five-year prevalence. China combines the largest patient pool with growing domestic development in antibodies, bispecifics, antibody–drug conjugates, and cellular therapies.

Satri-cel’s approval confirms that Chinese developers can commercialize gastric cancer innovations before competitors in the United States or Europe. Large specialist hospitals and a substantial biomarker-positive population also support faster recruitment into late-stage trials.

Japan and South Korea retain strong positions in endoscopic treatment, surgery, and gastric cancer research. Higher screening rates reduce metastatic treatment use per diagnosed patient but increase early intervention and curative-procedure volumes.

The United States remains the principal premium-pricing and regulatory-reference market. FDA approvals for pembrolizumab combinations, zolbetuximab, and perioperative durvalumab have expanded branded treatment across both resectable and metastatic disease.

European adoption will remain more dependent on health-technology assessment. NICE’s durvalumab recommendation and Scotland’s zolbetuximab decision indicate that medicines with mature survival evidence can gain public reimbursement despite high combination-treatment costs.

 

Company Positions Are Forming Around Treatment Sequences

Merck holds a broad checkpoint position through pembrolizumab in HER2-negative and HER2-positive advanced disease. AstraZeneca has extended durvalumab into perioperative treatment and participates with Daiichi Sankyo in later-line HER2 therapy through trastuzumab deruxtecan.

Astellas leads first-line CLDN18.2 antibody treatment with zolbetuximab, while Roche participates through companion diagnostics. CARsgen controls the first approved solid-tumor CAR-T position through satri-cel.

Jazz Pharmaceuticals and BeiGene could challenge the first-line HER2 standard if zanidatamab receives approval. Henlius is attempting to add another HER2 antibody while retaining trastuzumab as part of the regimen.

HER2 and CLDN18.2 are developing into treatment platforms rather than single-drug targets. HER2 can support first-line antibodies, checkpoint combinations, bispecifics, and later-line antibody–drug conjugates. CLDN18.2 can support first-line antibodies, bispecific combinations, antibody–drug conjugates, and CAR-T therapy.

Companies that retain target relevance across several treatment lines can generate more value from each biomarker-positive patient and extend product lifecycles through combination development.

 

Market Outlook

Stomach cancer treatment revenue will grow through greater treatment intensity rather than rapid incidence expansion. Perioperative durvalumab has added branded therapy to resectable disease. Pembrolizumab combinations sustain checkpoint inhibitor use in advanced treatment. Zolbetuximab has established CLDN18.2 testing and therapy as a reimbursable category. Satri-cel has opened a specialist cellular-therapy route for heavily pretreated patients.

Zanidatamab’s August 2026 regulatory decision is the next major first-line HER2 catalyst. Approval could increase competition, raise combination-treatment costs, and reduce trastuzumab’s role as the sole targeted backbone.

Patient identification, treatment completion, toxicity management, and reimbursement will determine adoption more than the number of available biological targets. Biomarker prevalence must be adjusted for assay thresholds, testing rates, disease stage, previous treatment, performance status, and regional access.

Randomized overall survival, durable event-free survival in resectable disease, reliable companion diagnostics, and activity after earlier targeted therapy will separate commercially viable products from crowded development programs. Stomach cancer treatment is becoming more segmented, but each successfully identified patient can generate substantially greater spending across perioperative therapy, advanced combinations, repeat testing, and later-line precision treatment.

 

Stomach Cancer Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 7.29 Billion
Revenue Forecast in 2032	USD 11.86 Billion
Overall Growth Rate	CAGR of 7.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Application, By End User, By Biomarker, By Geography
By Treatment Type	Chemotherapy, Immunotherapy, Targeted Therapy, Antibody–Drug Conjugates, Cellular Therapy, Surgery and Endoscopic Treatment, Radiation Therapy, Supportive Care
By Application	Early-Stage Stomach Cancer, Resectable Locally Advanced Stomach Cancer, Unresectable Locally Advanced Stomach Cancer, Metastatic Stomach Cancer, Recurrent Stomach Cancer
By End User	Hospitals, Specialty Cancer Centers, Ambulatory Infusion Centers, Surgical Centers, Cellular Therapy Centers
By Biomarker	HER2-Positive, PD-L1-Positive, CLDN18.2-Positive, MSI-High/dMMR, EBV-Positive, Biomarker-Negative or Unselected
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	- Rising adoption of precision oncology and biomarker-based stomach cancer therapies - Increasing demand for immunotherapy, targeted therapy, and antibody–drug conjugates - Growing cancer diagnosis rates and expansion of advanced oncology care infrastructure
Customization Option	Available upon request